Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Case of Lassa fever challenges UK hospitals

This article was originally published in Clinica

Executive Summary

Testing to diagnose in the UK a rare, isolated case of a viral haemorrhagic fever had to be referred to the Health Protection Agency (HPA), after the standard battery of tests for diseases associated with African travel proved negative. Lassa fever was eventually diagnosed; the patient had returned from Nigeria in early January. Following admission to London's Homerton hospital on January 8, it was not until January 22 that the diagnosis was made, according to the HPA. "The Homerton carried out testing for a wide range of common infections associated with travel to Africa, all of which tested negative. Samples were [then] referred to the HPA," said the agency. Lassa fever is endemic to Nigeria, but infections have occurred in neighbouring West African countries; it is seen only rarely in the UK among travellers returning from the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel